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Abstract
Introduction: The overexpression of nitric oxide synthase (NOS) has been found in tumours, including pituitary adenomas. It has also 
been found that NOS is overexpressed in human spontaneous pituitary adenomas. The question arises whether NOS and its product, 
nitric oxide (NO), are involved in pituitary tumourigenesis. To investigate this question, in the present paper we examine the effects of 
NOS inhibition on the development of diethylstilbestrol (DES)-induced prolactin–secreting pituitary tumours in rats.
Material and methods: Thirty male Fisher 344 rats, four weeks old, were submitted to subcutaneous implantation of a silastic capsule 
containing DES (10 mg/capsule) or of an empty capsule. Six weeks after implantation, some of the DES-treated animals received a NOS 
inhibitor, N-nitro-l-arginine methyl ester (NAME), 1 mg/mL, in their drinking water, for the subsequent 14 days. Eight weeks after the 
implantation, all the animals were sacrificed, their pituitaries were weighed, and samples of heart blood were collected for prolactin (PRL) 
and vascular endothelial growth factor (VEGF) measurements.
Results: It was found that DES implantation significantly increased pituitary mass, as well as PRL and VEGF concentrations in blood 
serum. On the other hand, the administration of NAME did not affect significantly either VEGF concentration or pituitary mass. On the 
other hand, it did induce a further increase in PRL levels.
Conclusions: These findings indicate that NO is involved in oestrogen-induced hyperprolactinaemia, but does not play a crucial role in 
oestrogen-induced pituitary tumourigenesis. (Pol J Endocrinol 2012; 63 (2): 115–118)
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Streszczenie
Wstęp: W licznych nowotworach, w tym także gruczolakach przysadki, stwierdzono zwiększoną ekspresję syntazy tlenku azotu (NOS). 
Powstaje pytanie, czy NOS oraz jej produkt — tlenek azotu (NO) biorą udział w patogenezie guzów przysadki. W celu zbadania tego 
zagadnienia autorzy niniejszej pracy prześledzili wpływ zahamowania aktywności NOS na rozwój prolaktynowego guza przysadki 
wywołanego dietylstilbestrolem (DES) u szczurów.
Materiał i metody: Czterotygodniowym szczurom samcom szczepu Fisher 344 implantowano podskórnie silastikowe kapsułki zawierające 
10 mg DES w kapsułce lub puste kapsułki. Sześć tygodni po implantacji część zwierząt, którym implantowano kapsułki z DES, otrzymywała 
inhibitor NOS — ester metylowy N-nitro-l-argininy (NAME) w wodzie do picia, w stężeniu 1 mg/ml, przez 14 dni. Osiem tygodni po 
implantacji kapsułek zwierzęta uśmiercono, pobrano i zważono przysadki oraz próbki krwi z serca w celu oznaczenia stężeń prolaktyny 
(PRL) i czynnika wzrostu śródbłonków naczyniowych (VEGF).
Wyniki: Stwierdzono, że implantacja DES znamiennie zwiększa masę przysadki oraz stężenia PRL i VEGF w surowicy krwi. Równoczesne 
podawanie NAME nie ma istotnego wpływu na masę przysadki ani stężenie VEGF, natomiast powoduje dalszy wzrost stężenia PRL.
Wnioski: Uzyskane wyniki wskazują, że NO wpływa na hiperprolaktynemię indukowaną DES, ale nie odgrywa istotnej roli w rozwoju 
guza prolaktynowego indukowanego estrogenem. (Endokrynol Pol 2012; 63 (2): 115–118)
Słowa kluczowe: tlenek azotu, prolaktyna, VEGF, guz przysadki wywołany estrogenem
Introduction
Nitric oxide (NO), a molecule generated from arginine 
by an enzyme called nitric oxide synthase (NOS), plays 
an important role as a messenger involved in numer-
ous regulatory functions within the living organism. 
The best known role of NO is relaxation of the blood 
vessels [1]. More recently, overexpression of NOS has 
been found in several human tumours [2–6] including 
pituitary adenomas [7, 8]. In a murine glioma model, 
NOS inhibition results in slowing tumour growth [9]. 
Overexpression of NOS is associated with poor sur-
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vival in patients suffering from cervical cancer [10] and 
oestrogen receptor-negative breast cancer [11]. On the 
other hand, inducible NOS expression is considered 
to be a favourable prognostic marker in early-stage 
cervical cancer [12]. It has also been found that NOS 
is overexpressed in experimental diethylstrilbestrol 
(DES)-induced prolactinomas in rats [8, 13] compared 
to normal rat anterior pituitary gland.
The question arises as to whether NOS and its 
product, NO, are involved in pituitary tumourigen-
esis. To test this question, in the present paper we 
examined the effects of NOS inhibition on the devel-
opment of DES-induced prolactin-secreting pituitary 
tumours in rats. Numerous studies have shown the 
increase of vascular endothelial growth factor (VEGF) 
expression in tumours and a correlation between 
VEGF levels and microvascular density [14, 15]. The 
development of pituitary adenomas, like other solid 
tumours, also depends on neo-angiogenesis. VEGF 
levels have been found to be elevated in patients with 
pituitary tumours [16–18] and the administration of 
anti-angiogenic agents have inhibited the growth of 
experimental oestrogen-induced rat prolactinoma 
[19]. On the other hand, vascularisation of pituitary 
adenomas is poorer than that of a normal pituitary, 
and VEGF levels do not correlate with microvascular 
density in human pituitary adenomas [17]. In pitui-
tary adenomas, VEGF receptors have been found to 
be expressed not only in endothelial cells of intratu-
moural blood vessels, but also in tumoural cells [20]. It 
has been suggested that VEGF in pituitary adenomas 
acts not only as a stimulator of angiogenesis, but di-
rectly promotes growth of tumoural cells. The recent 
in vitro experiments of Zatelli et al. [21], who found 
that the somatostatin analogue pasireotide inhibits 
the viability of pituitary adenoma cells in culture 
acting via VEGF suppression, confirm this hypo-
thesis. Because of that, we also examined the effect 
of NO inhibition on VEGF concentrations in blood 
serum during DES-induced pituitary tumourigenesis.
Material and methods
Induction of pituitary tumours in rats
Thirty male Fisher 344 rats, four weeks old, were 
submitted under ketamine anaesthesia to subcutane-
ous implantation of a silastic capsule containing DES 
(10 mg/capsule, 20 animals) or of an empty capsule 
(control = ten rats). Six weeks after implantation, ten 
DES-treated animals received a NOS inhibitor, N-ni-
tro-l-arginine methyl ester (NAME), 1 mg/mL in their 
drinking water, for the subsequent 14 days. Another 
DES-treated group (ten rats) was given water that did 
not contain NAME. Eight weeks after the implantation, 
all the animals were sacrificed by decapitation, the 
pituitaries were weighed, and samples of heart blood 
were collected for prolactin and vascular endothelial 
growth factor (VEGF) measurements. The experiment 
was approved by the Ethical Committee for Animal 
Experimentation in Lodz (decision Ł/BD/150).
Prolactin assay
Prolactin (PRL) concentrations in the blood serum were 
measured using rat prolactin (rPRL) [125I] — Biotrak As-
say System with Magnetic Separation (Amersham, UK, 
Code: RPA 553). The assay sensitivity was: 0.7 ng/mL 
and the coefficients of inter- and intra-assays variations 
were 8.3% and 10.5% respectively.
VEGF assay
Vascular endothelial growth factor (VEGF) was meas-
ured in the blood serum using ELISA mouse/rat VEGF 
assay kits (Quantikine, R&D Systems, Minneapolis, 
MN, USA).
Statistical analysis
Statistical analysis was performed by means of ANOVA 
test followed by LSD test.
Results
The results are presented in Figures 1–3. As can be 
seen there, DES implantation induced an approxi-
mately three-fold increase in pituitary mass (DES 
Figure 1. Effects of diethylstilbestrol alone (DES), and DES 
+ N-nitro-l-arginine methyl ester (NAME), on the anterior 
pituitary mass in male Fisher 344 rats (means ± SEM); C — 
control
Rycina 1. Wpływ samego dietylstilbestrolu (DES) oraz DES 
łącznie z estrem metylowym N-nitro-l-argininy (NAME) na 
masę przysadki szczurów samców szczepu Fisher 344 (średnie 
± SEM); C — grupa kontrolna
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18.99 ± 1.26 mg vs. control 6.15 ± 0.36 mg, p < 0.001, 
Figure 1) as well as a 27-fold increase in PRL con-
centration in blood serum (DES 356 ± 86.8 ng/mL 
vs. 13.1 ± 3.5 ng/mL, p < 0.001, Figure 2). Moreover, 
the mean blood serum concentration of VEGF was in-
creased approximatively three-fold in DES-implanted 
animals (171.7 ± 10.4 vs. 51.8 ± 6.0 pg/mL, p < 0.001, 
Figure 3). The simultaneous administration of the NOS 
inhibitor, NAME, did not affect VEGF concentrations 
(DES 171.7 ± 10.4 vs. DES+NAME 180.8 ± 11.6 pg/mL) 
and slightly, but not significantly, decreased the pi-
tuitary mass (DES + NAME 16.5 ± 1.31 mg vs. DES 
18.99 ± 1.26 mg, Figure 1), but induced a further increase 
in PRL level (DES + NAME 769 ± 120 ng/mL vs. DES 
356 ± 86.8 ng/mL, p < 0.01, Figure 2).
Discussion
As expected, DES implantation resulted in sharp in-
creases of pituitary mass and PRL secretion. We found 
in our previous studies that prolactin cells undergo 
hyperplasia and form the vast majority of the adeno-
matous structure [13]. A sharp increase concerns also 
the vascular endothelial growth factor (VEGF), which 
confirms its involvement in pituitary tumourigenesis via 
pro-angiogenic, and, possibly, direct growth-promoting 
action [18, 19, 21]. The observed overexpression of NOS 
in both spontaneous human pituitary adenomas and in 
oestrogen-induced experimental rat pituitary tumours, 
suggested a role of NO in tumoural pituitary tumouri-
genesis [8]. Such a possibility is supported by a study 
showing the antiapoptotic effect of NO on the anterior 
pituitary cells [22]. Although we did not measure directly 
the activity of NOS in our study, the same dosage of 
NAME has been found to decrease NOS activity in the 
rat thyroid gland by more than 75% [23]. However, the 
inhibition of NO generation affected neither pituitary 
growth nor serum VEGF concentrations, as was shown 
in the present study. Interestingly, NO inhibition did 
not suppress, and in fact even enhanced, DES-induced 
hyperprolactinaemia. Earlier studies concerning the rela-
tion between NO and PRL secretion resulted in divergent 
effects, depending on the experimental models. NO is 
found either to enhance [24, 25] or to inhibit [26–28] PRL 
secretion. The mechanism of the latter effect, which cor-
roborates with our study, may involve the PRL-inhibiting 
action of dopamine. It has been shown that dopamine’s 
effect on PRL release in vitro is suppressed by NO inhibi-
tors [23]. Moreover, NO affects the central dopaminergic 
system; for instance, the NO synthesis inhibitor has been 
shown to enhance the amphetamine-induced dopamine 
release in the neostriatum [29].
Conclusions
Summing up, although NO synthesis inhibition 
enhances oestrogen-induced hyperprolactinaemia, NO 
seems not to play an important role in oestrogen-in-
duced pituitary hyperplasia and, possibly, tumouri-
genesis.
Figure 3. Effects of diethylstilbestrol alone (DES), and DES + 
+ N-nitro-l-arginine methyl ester (NAME), on vascular 
endothelial growth factor (VEGF) blood serum concentrations in 
male Fisher 344 rats (means ± SEM); C — control
Rycina 3. Wpływ samego dietylstilbestrolu (DES) oraz DES łącznie 
z estrem metylowym N-nitro-l-argininy (NAME) na stężenia czynnika 
wzrostu śródbłonka naczyniowego (VEGF) w surowicy krwi szczurów 
samców szczepu Fisher 344 (średnie ± SEM); C — grupa kontrolna
Figure 2. Effects of diethylstilbestrol alone (DES), and DES + 
+ N-nitro-l-arginine methyl ester (NAME), on prolactin (PRL) 
blood serum concentrations in male Fisher 344 rats (means 
± SEM); C — control
Rycina 2. Wpływ samego dietylstilbestrolu (DES) oraz DES 
łącznie z estrem metylowym N-nitro-l-argininy (NAME) na 
stężenia prolaktyny (PRL) w surowicy krwi szczurów samców 
szczepu Fisher 344 (średnie ± SEM); C — grupa kontrolna
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